The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The impact of adjuvant endocrine therapy (AET) omission in ER-low (1-10%) early-stage breast cancer.
 
Grace Mei Yee Choong
No Relationships to Disclose
 
Tanya L. Hoskin
No Relationships to Disclose
 
Judy Caroline Boughey
Honoraria - PeerView; PER; UpToDate
Consulting or Advisory Role - CairnSurgical; SymBioSis (Inst)
Research Funding - Lilly (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending - METHODS AND MATERIALS FOR ASSESSING CHEMOTHERAPY RESPONSIVENESS AND TREATING CANCER (Inst)
Travel, Accommodations, Expenses - Endomagnetics; Endomagnetics
 
James N. Ingle
No Relationships to Disclose
 
Matthew P. Goetz
Consulting or Advisory Role - ARC Therapeutics (Inst); AstraZeneca (Inst); BioTheryX; Blueprint Medicines (Inst); Engage Health Media (Inst); Genzyme (Inst); Laekna Therapeutics; Lilly (Inst); Novartis (Inst); Rna Diagnostics (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Tersera
Research Funding - AstraZeneca (Inst); Atossa Genetics (Inst); Lilly (Inst); Loxo (Inst); Pfizer (Inst); Sermonix Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Development of Human Tumor Xenografts from Women with Breast Cancer Treated with Neoadjuvant Chemotherapy (Inst); Methods and Materials for Assessing Chemotherapy Responsiveness and Treating Cancer; METHODS AND MATERIALS FOR USING BUTYRYLCHOLINESTERASES TO TREAT CANCER
Travel, Accommodations, Expenses - Lilly (Inst)